Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

RLAY stock hub

Relay Therapeutics, Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

RLAYis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

2.4B

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

RLAY

In the news

Latest news · RLAY

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROE-40

P25 -105.6P50 -46.5P75 -3.1

ROIC-25.7

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All RLAY market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

202

Groups with data

Currency

USD

Showing 202 of 202 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001812364
Company name	Relay Therapeutics, Inc.
Country	United States
Country code	US
Cusip	75943R102
Employees	192
Employees Change	-69%
Employees Change Percent	-26.44
Enterprise value	$1.8B
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2020-07-16
Isin	US75943R1023
Last refreshed	2026-05-10
Market cap	$2.4B
Market cap category	Mid-Cap
Price	$12.76
Price currency	USD
Rev Per Employee	55,604.17x
Sector	Healthcare
Sic	2836
Symbol	RLAY
Website	https://www.relaytx.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-11.16%
EV/Sales	171.8x
FCF yield	-8.73%
P/B ratio	3.76x
P/S ratio	228.98x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Gross Profit	$-245.6M
Net Income	$-272.7M
Net Income Growth Quarters	6%
Net Income Growth Years	2%
Pretax Margin	-2,554.37%
Profit Per Employee	$-1.4M
ROA	-24.72
Roa5y	-22.39
ROCE	-44.26
ROE	-40.01
Roe5y	-40.14
ROIC	-25.7

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	332.98%
Cagr3y	4.23%
Cagr5y	-15.43%
EPS Growth Quarters	6
EPS Growth Years	2
Revenue Growth	39.03x
Revenue Growth Q	-60.93x
Revenue Growth Years	1x
Revenue Growth3 Y	107.9x
Revenue Growth5 Y	-33.74x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.01
Assets	$699.6M
Cash	$642.1M
Current Assets	$658.5M
Current Liabilities	$29.8M
Debt	$31.6M
Debt Equity	$0.05
Equity	$642.2M
Liabilities	$57.4M
Long Term Assets	$41.2M
Long Term Liabilities	$27.7M
Net Cash	$610.5M
Net Cash By Market Cap	$24.97
Net Cash Growth	-7.95%
Net Debt Equity	$-0.95
Tangible Book Value	$642.2M
Tangible Book Value Per Share	$3.39
WACC	13.71

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	22.13
Net Working Capital	$-9.5M
Quick ratio	21.58
Working Capital	$628.7M
Working Capital Turnover	$0.02

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-14.28%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	332.54%
200-day SMA	7.86
3Y total return	13.22%
50-day SMA	12.26
50-day SMA vs 200-day SMA	50over200
5Y total return	-56.75%
All Time High	64.37
All Time High Change	-80.18%
All Time High Date	2021-01-20
All Time Low	1.78
All Time Low Change	618.87%
All Time Low Date	2025-04-07
ATR	0.94
Beta	1.75
Beta1y	1.49
Beta2y	2.13
Ch YTD	50.83
High	12.87
High52	17.32
High52 Date	2026-04-17
High52ch	-26.33%
Low	12.4
Low52	2.67
Low52 Date	2025-05-15
Low52ch	377.9%
Ma50ch	4.12%
Premarket Change Percent	0.72
Premarket Price	$12.6
Premarket Volume	38,048
Price vs 200-day SMA	62.44%
RSI	45.3
RSI Monthly	62.9
RSI Weekly	61.42
Sharpe ratio	2.38x
Sortino ratio	4.41
Total Return	-14.28%
Tr YTD	50.83
Tr1m	-5.34%
Tr1w	0.31%
Tr3m	43.05%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	9
Analyst Count Top	2
Analyst Price Target Top	$21
Analyst Ratings	Strong Buy
Analyst Ratings Top	Buy
Earnings EPS Estimate	$-0.36
Earnings Revenue Estimate	6,790,000x
Earnings Revenue Estimate Growth	-11.58x
Operating Income	$-296.5M
Operating margin	-2,776.9
Price target	$20.56
Price Target Change	$61.13
Price Target Change Top	$64.58

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	115,914,212%
Float Percent	60.5%
Shares Insiders	2.04%
Shares Institutions	52.94%
Shares Out	191,586,165
Shares Qo Q	3.72%
Shares Yo Y	14.28%
Short Float	23.29%
Short Ratio	8.43
Short Shares	14.09

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-267M
Average Volume	3,130,169.05x
Bv Per Share	3.39
CAPEX	$-26,000
Ch1m	-5.34
Ch1w	0.31
Ch1y	332.5
Ch3m	43.05
Ch3y	13.22
Ch5y	-56.75
Ch6m	110.9
Change	2%
Change From Open	1.19
Close	12.51
Days Gap	0.8
Depreciation Amortization	2,853,000
Dollar Volume	23,358,456
Earnings Date	2026-05-05
Earnings Time	amc
EBIT	$-296.5M
EBITDA	$-293.6M
EPS	$-1.57
F Score	4
FCF	$-213.4M
FCF EV Yield	-11.63x
FCF Per Share	$-1.11
Financing CF	140,386,000
Fiscal Year End	December
Founded	2,015
Investing CF	183,235,000
Ipr	-36.2
Iprfo	-63.54
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-05
Last Report Date	2026-03-31
Last Split Type	Never
Last10k Filing Date	2026-02-26
Ma150	9.16
Ma150ch	39.27%
Ma20	14.44
Ma20ch	-11.64%
Net CF	110,264,000
Next Earnings Date	2026-08-06
Open	12.61
Optionable	Yes
Position In Range	76.6
Post Close	12.76
Postmarket Change Percent	1.07
Postmarket Price	$12.9
Ppne	39,815,000
Pre Close	12.51
Price Date	2026-05-08
Ptbv Ratio	3.81
Relative Volume	0.58x
Revenue	10,676,000x
SBC By Revenue	502.35x
Share Based Comp	53,631,000
Tr6m	110.91%
Us State	Massachusetts
Volume	1,830,600
Z Score	5.86

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does RLAY pay a dividend?

Capital-return profile for this ticker.

Performance

RLAY stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns RLAY?

Insider, institutional, and short-interest positioning.

Institutional ownership

+52.9%

Float: +60.5% of shares outstanding

Insider ownership

+2.0%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

RLAY momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

45.3

Neutral momentum band

Price vs 200-day MA

+62.4%

50/200-day relationship not available

Beta (5Y)

1.75

More volatile than the market

Sharpe ratio

2.38

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About RLAY

Hub-level FAQ points readers to the deeper analysis pages.

What is the current RLAY stock rating?

Relay Therapeutics, Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full RLAY analysis?

The full report lives at /stocks/RLAY/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for RLAY?

The latest report frames RLAY around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the RLAY page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.